Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. (Q39732167)

14 September 2017

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. (English)

1 reference

14 September 2017

C F Cheok

1

1 reference

14 September 2017

N Kua

series ordinal

2

1 reference

14 September 2017

P Kaldis

series ordinal

3

1 reference

14 September 2017

D P Lane

series ordinal

4

1 reference

14 September 2017

5 March 2010

1 reference

Cell Death & Differentiation

14 September 2017

1 reference

14 September 2017

17

1 reference

14 September 2017

9

1 reference

14 September 2017

1486-1500

1 reference

https://scigraph.springernature.com/pub.10.1038/cdd.2010.18

14 September 2017

0 references

cites work

The role of inhibitory phosphorylation of CDC2 following DNA replication block and radiation-induced damage in human cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

TAp73alpha binds the kinetochore proteins Bub1 and Bub3 resulting in polyploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Cancer. p53, guardian of the genome

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Aurora kinases as anticancer drug targets

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Human cyclin A is required for mitosis until mid prophase

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Cyclin A2 regulates nuclear-envelope breakdown and the nuclear accumulation of cyclin B1.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

The central role of CDE/CHR promoter elements in the regulation of cell cycle-dependent gene transcription.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

p53 regulates a G2 checkpoint through cyclin B1

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Strategies for therapeutic targeting of the p53 pathway in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

p73 suppresses polyploidy and aneuploidy in the absence of functional p53

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Modelling Myc inhibition as a cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Cell cycle progression after cleavage failure: mammalian somatic cells do not possess a "tetraploidy checkpoint".

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

The impact of p53 and p73 on aneuploidy and cancer

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Cdk2 knockout mice are viable

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Identification and classification of p53-regulated genes

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.18

7 January 2021

Identifiers

DOI

10.1038/CDD.2010.18

1 reference

Dimensions Publication ID

14 September 2017

0 references

1 reference